Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs >

Jounce Therapeutics Inc. (JNCE)

Add JNCE Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 5/11/2017 1:49:16 PM - Followers: 1 - Board type: Free - Posts Today: 0

Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company. The Company is engaged in developing therapies that enable the immune system to attack tumors. Through the use of its Translational Science Platform, the Company first focuses on specific cell types within tumors to prioritize targets, and then identify related biomarkers designed to match the right therapy to the right patient. The Company’s lead product candidate, JTX-2011, is a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator (ICOS), a protein on the surface of certain T cells found in a range of solid tumors. The Company has initiated JTX-2011 multi-arm Phase I/II clinical trial in patients with solid tumors. The Company is also developing JTX-4014 for use in future combinations with JTX-2011, as well as for use in combination with other future product candidates. The Company is developing JTX-4014, a fully human Immunoglobulin G 4 (IgG4) monoclonal antibody.
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
JNCE News: Loncar Cancer Immunotherapy Index Conducts Semi-Annual Rebalance 06/21/2017 08:30:00 AM
JNCE News: OncoSec Announces Technology Access Program Agreement with Jounce Therapeutics, Inc. 06/12/2017 06:01:00 AM
JNCE News: Jounce Therapeutics Presents Phase 1 Data from ICONIC Study of JTX-2011 in Patients with Advanced Solid Tumors at 2017 ASCO A... 06/05/2017 09:00:00 AM
JNCE News: Current Report Filing (8-k) 05/23/2017 11:58:51 AM
JNCE News: Jounce Therapeutics to Present Phase 1 Data from JTX-2011 ICONIC Trial at 2017 American Society of Clinical Oncology Annual M... 05/17/2017 05:00:00 PM
#1   JNCE bullish 24.61 stocktrademan 05/11/17 01:49:16 PM